{"analyses":[{"ciLowerLimit":"0.17","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.11","estimateComment":"hazard ratio: blinatumomab + chemotherapy vs. chemotherapy alone","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.41","paramType":"Hazard Ratio (HR)","paramValue":"0.59","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"Median OS not reached The 95% confidence intervals were not calculable because an insufficient number of participants reached the event at the final time point for assessment.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Median OS not reached The upper limit of the 95% confidence interval was not calculable because an insufficient number of participants reached the event at the final time point for assessment.","groupId":"OG001","lowerLimit":"30.2","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"description":"OS was defined as time from allogeneic transplant to death of any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients who proceed to allogeneic blood or marrow transplant after treatment with blinatumomab and chemotherapy.","id":"OG000","title":"MRD Negative Patients Receiving Blinatumomab + Chemotherapy and Then Allogeneic Transplant"},{"description":"Patients who proceed to allogeneic blood or marrow transplant after treatment with chemotherapy.\n\n.","id":"OG001","title":"MRD Negative Patients Receiving Chemotherapy and Then Allogeneic Transplant"}],"paramType":"MEDIAN","populationDescription":"MRD negative patients who proceeded to allogeneic transplant after treatment with blinatumomab plus chemotherapy or chemotherapy alone were included in this analysis.","reportingStatus":"POSTED","timeFrame":"Assessed every 3 months for 2 years, then every 6 months for 3 years, then annually for 5 years","title":"OS Among MRD Negative Patients Who Proceed to Allogeneic Transplant on Study","type":"SECONDARY","unitOfMeasure":"months"}